Figure 2
Figure 2. OS and time to AML progression in MDS patients. OS (A) and time to AML progression (B) in MDS patients according to SRSF2 mutation status (log-rank test) are shown. OS (C) and time to AML progression (D) in MDS patients according to U2AF1 mutation status (log-rank test) are shown.

OS and time to AML progression in MDS patients. OS (A) and time to AML progression (B) in MDS patients according to SRSF2 mutation status (log-rank test) are shown. OS (C) and time to AML progression (D) in MDS patients according to U2AF1 mutation status (log-rank test) are shown.

Close Modal

or Create an Account

Close Modal
Close Modal